Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.

Details

Language :

English

ISSN :

03618609

Volume :

97

Issue :

11

Database :

Complementary Index

Journal :

American Journal of Hematology

Publication Type :

Academic Journal

Accession number :

159611571

Full Text :

https://doi.org/10.1002/ajh.26689